^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Non-Hodgkin’s Lymphoma |
| Drug: | Poteligeo (mogamulizumab-kpkc) (CCR4 receptor antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
...the panel has included mogamulizumab (off-label use) as a preferred single agent second-line therapy option for relapsed or refractory ATLL.
